Research Meetings

Share
Print
Share
Print

Presentations from the Small Cell Lung Cancer (SCLC) Research Consortium Annual Meeting and the Consortium’s Monthly Webex Meetings are posted as a reference.

Annual Consortium Meetings

IASLC 2017 Small Cell Lung Cancer Meeting
March 15-17, 2017
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda
 
2018 Small Cell Lung Cancer Consortium Meeting
March 15-16, 2018
NCI Shady Grove, Rockville, MD
Program Agenda
 
IASLC 2019 Small Cell Lung Cancer Meeting
April 3-5, 2019
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda
 
2020 Small Cell Lung Cancer Consortium Meeting
March 26-27, 2020
Bethesda North Marriott Hotel & Conference Center
Cancelled

Monthly Virtual Meetings

2020

“Genomic and transcriptomic features of relapsed SCLC”
Siddhartha Devarakonda, MD

Assistant Professor of Medicine
Siteman Cancer Center
Washington University School of Medicine
 
“Molecular comparison of PDX/CDX models with primary specimens”
Luc Girard, PhD

Assistant Professor, Hamon Center for Therapeutic Oncology Research
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
 
“Deep proteomic profiling of SCLC cell lines reveals a MYC-centric neuroendocrine signature”
Ehsan Irajizad, PhD
Biomathematics and Biostatistics
MD Anderson Cancer Center
 
“MYC-driven polyamine signature with a protein panel for early detection”
Johannes Fahrmann, PhD

Instructor, Clinical Cancer Prevention
MD Anderson Cancer Center
 
“Skp2 E3 ubiquitin ligase: a downstream target in RB1-deficient SCLC”
Edward Schwartz, PhD

Professor, Department of Medicine (Oncology)
Professor, Department of Molecular Pharmacology
Albert Einstein College of Medicine
 
“A ubiquitin E3 ligase mediates resistance to PARP inhibitors in SCLC”
Benjamin Lok, MD

Assistant Professor, Department of Radiation Oncology
Medical Biophysics, Institute of Medical Science
Princess Margaret Cancer Centre, University of Toronto

“Functional screens and mouse models identify MAX as a tumor suppressor in SCLC”
Arnaud Augert, PhD 

Postdoctoral Fellow (MacPherson Lab)
Human Biology & Public Health Sciences Divisions
Fred Hutchinson Cancer Research Center 

“Transcriptional programs and immune activation define four major subtypes of SCLC”
Carl Gay, MD PhD

Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center

“MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate”
Trudy Oliver, PhD

Associate Professor, Oncological Sciences
Huntsman Cancer Institute, University of Utah

“The tuft cell variant of SCLC”
Chris Vakoc, MD PhD

Professor, CSHL Cancer Center
Cold Spring Harbor Laboratory

“Plasticity of MHC class I expression and immune rejection”
David Barbie, MD

Associate Director, Belfer Center for Applied Cancer Research
Associate Professor, Lowe Center for Thoracic Oncology 
Dana-Farber Cancer Institute

“CDK7 inhibition potentiates genome instability triggering anti-tumor immunity”
Hua Zhang, PhD

Postdoctoral Fellow, Wong Laboratory
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health

“A new ASCL1+ subtype, A2, forms a plastic, transit-amplifying compartment of SCLC tumors”
Sarah Groves

Graduate Student, Quaranta Laboratory
Quantitative and Chemical Biology Program
Vanderbilt University School of Medicine

“Computational Modeling of Subtype Interactions in SCLC to Modulate Tumor Composition”
Leonard Harris, PhD

Department of Biochemistry
Vanderbilt University School of Medicine

“Epigenome-wide DNA methylation analysis of SCLC cell lines suggests potential chemotherapy targets”
Julia Krushkal, PhD

Biometric Research Program
Computational & Systems Biology Branch
National Cancer Institute

“On the origins of SCLC”
Harold Varmus, MD

Lewis Thomas University Professor
Meyer Cancer Center, Weill Cornell Medicine

“Histologic transformation in lung cancer through basal cell intermediates”
Eric Gardner, PharmD, PhD

Postdoctoral Fellow, Varmus Lab
Meyer Cancer Center, Weill Cornell Medicine

“scRNASeq reveals intratumoral heterogeneity in therapy resistance”
Allison Stewart, PhD

Research Scientist, Byers Laboratory
MD Anderson Cancer Center

“Novel Chemotherapy-stable subpopulations are conserved across multiple PDX models”
Jonathan Lehman MD, PhD

Instructor in Medicine, Division of Hematology/Oncology
Vanderbilt University Medical Center

2019

“Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung cancer”
Ramaswamy Govindan, MD

Anheuser Busch Endowed Chair in Medical Oncology 
Professor of Medicine, Division of Oncology 
Director, Section of Medical Oncology 
Washington University School of Medicine, Siteman Cancer Center 
Obi Griffith, PhD
Assistant Professor of Medicine, Division of Oncology 
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine, Siteman Cancer Center 
Trudy Oliver, PhD
Associate Professor, Department of Oncological Sciences, 
Cell Response and Regulation Cancer Center Program 
Huntsman Cancer Institute, University of Utah 

“Using patient-derived models to understand drug responses in SCLC “
Anna Farago, MD PhD

Assistant Professor, Medicine, Harvard Medical School
Assistant, Medicine, Massachusetts General Hospital
Dana Farber/Harvard Cancer Institute 
Benjamin Drapkin, MD, PhD
Instructor, Medicine, Massachusetts General Hospital
Nicholas Dyson, PhD
Professor of Medicine, Mary B. Saltonstall Chair in Oncology, Harvard Medical School
Geneticist, Center for Cancer Research
James and Shirley Curvey MGH Research Scholar
Scientific Director, Mass General Cancer Center

“Integrated Protometabolic Analysis Reveals Metabolic Vulnerabilities in SCLC” 
Eric Haura, MD

Director, Lung Comprehensive Research Center
Co-Program Leader, Chemical Biology and Molecular Medicine Program 
Department of Thoracic Oncology
H. Lee Moffitt Cancer Center & Research Institute

“Discovering tumor vulnerabilities linked to de-differentiation: Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies”
Thomas Graeber, PhD

Director, UCLA Metabolomic Center 
Professor, Molecular & Medical Pharmacology 
Member, Crump Institute for Molecular Imaging at UCLA
UCLA Molecular Biology Institute 

“Phenotype interactions in SCLC development and detection” 
Christine Lovly, MD, PhD

Co-Leader, Translational Research and Interventional Oncology Research Program
Associate Professor of Medicine (Hematology/Oncology)
Vanderbilt Ingram Cancer Center 
Alissa Weaver, MD, PhD
Professor, Cell and Developmental Biology & Pathology, 
Microbiology, and Immunology
VU Center for Cancer Systems Biology
Vanderbilt Ingram Cancer Center 

“Developing ASCL1 and NEUROD1 lineage oncogene targeted therapy for small cell lung cancer” 
John Minna, MD

Director, Hamon Center for Therapeutic Oncology Research, 
The Moncrief Center for Cancer Genetics,
Co-Director of the Experimental Therapeutics Program, Simmons Cancer Center 
Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology 
Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Jane Johnson, PhD
Professor and Vice Chair, Department of Neuroscience 
Shirley and William S. McIntyre Distinguished Chair in Neuroscience
UT Southwestern Medical Center

“Targeting BCAT1 and branched-chain amino acid metabolism for the detection and prevention of SCLC”
Kwon-Sik Park, PhD 

Associate Professor, Microbiology, Immunology, and Cancer Biology
University of Virginia, School of Medicine

“RB1 WT SCLC and RB1 WT, KEAP1 WT, STK11 WT neuroendocrine negative LCNEC”
Dmitriy Sonkin, PhD

Computational Biologist, Computational & Systems Biology Branch
Division of Cancer Treatment & Diagnosis (DCTD)
National Cancer Institute 

2018

“Tissue Microarray (TMA) Project” 
Afshin Dowlati, MD

Professor, Department of Medicine Division of Hematology and Oncology, School of Medicine
Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center
Case Western Reserve University 
Gary Wildey, PhD
Program Manager
Case Comprehensive Cancer Center 
Case Western Reserve University 

“RB1 Loss Drives Prostate Cancer Lineage Plasticity and Therapeutic Resistance”
Leigh Ellis, PhD

Assistant Professor, Pathology, Harvard Medical School
Assistant Professor of Pathology, Oncologic Pathology
Dana-Farber Cancer Institute, Harvard Cancer Center

“Center for Systems Biology of Small Cell Lung Cancer”
Vito Quaranta, MD

Department of Biochemistry, Professor in Biochemistry & Pharmacology 
Director of Quantitative Systems Biology Center 
Co-Director of The Center for Matrix Biology
Vanderbilt University 

“Understanding Different Subsets of Small Cell Lung Cancer”
David MacPherson, PhD

Associate Member, Human Biology Division
Associate Member, Public Health Sciences Division
Fred Hutchinson Cancer Research Center 

“Enhancing Small Cell Lung Cancer Therapy with Pharmacological Ascorbate”
Bryan Allen, MD

Associate Professor of Radiation Oncology
Carver College of Medicine 
University of Iowa Health Care

“A Tuft Cell Variant of Small Cell Lung Cancer”
Chris Vakoc, MD, PhD
CSHL Cancer Center 
Gene Regulation and Cell Proliferation 
Cold Springs Harbor Laboratory 

SCLC Research Project Presentations